脑血流动力学与左西孟旦在脑血管痉挛及蛛网膜下腔出血患者中的应用:一项基于灌注CT的观察性影像学研究
本研究为神经外科ICU数据库的回顾性分析,纳入2018年1月至2022年7月因动脉瘤性蛛网膜下腔出血并因脑血管痉挛对其他治疗无反应而接受左西孟旦治疗的患者,共纳入21例,其中16例可进行CTP分析。通过自动定量测量,比较左西孟旦给药前后少血区的达峰时间(Tmax)、相对脑血容量(rCBV)和相对脑血流(rCBF)。结果显示Tmax从治疗前14.4秒(IQR 9.1-21)降至治疗后7.1秒(IQR 5.5-8.1)(p < 0.001),rCBV和rCBF保持稳定;6例未发生迟发性脑缺血所致脑梗死的患者亚组中rCBV和rCBF约增加10%,但未达统计学显著。作者认为左西孟旦可能引起脑血管扩张,但研究设计无法区分左西孟旦效应与血管痉挛自然演变,需进一步研究。
要点
- 在难治性脑血管痉挛患者中,左西孟旦使用后少血区Tmax从14.4秒(IQR 9.1-21)降至7.1秒(IQR 5.5-8.1),p < 0.001。
- 左西孟旦使用前后rCBV(94% vs 89%,p = 0.63)和rCBF(85% vs 87%,p = 0.98)保持稳定,无显著变化。
- 6例未发生迟发性脑缺血所致脑梗死的患者亚组中,rCBV从85%(IQR 79-99)升至95%(IQR 88-112)(p = 0.21),rCBF从81%(IQR 76-87)升至89%(IQR 84-99)(p = 0.4),约增加10%但未达统计学显著。
- 尽管Tmax显著降低,但仍处于异常水平,提示持续存在脑血管痉挛。
- 作者认为左西孟旦可能引起脑血管扩张,但因研究设计无法量化左西孟旦效应与血管痉挛自然演变的区别,需进一步研究。
适用人群与场景
- 2018年1月至2022年7月神经外科ICU收治的动脉瘤性蛛网膜下腔出血患者。
- 因脑血管痉挛对其他治疗无反应而接受左西孟旦治疗的患者。
- 共纳入21例,其中16例可进行CTP分析。
研究设计与关键结果
- 研究类型:回顾性分析神经外科ICU数据库;样本量21例,其中16例可进行CTP分析;人群为动脉瘤性蛛网膜下腔出血并难治性脑血管痉挛接受左西孟旦治疗的患者;干预为左西孟旦;主要终点为左西孟旦给药前后少血区CTP定量参数比较。
- Tmax从治疗前14.4秒(IQR 9.1-21)降至治疗后7.1秒(IQR 5.5-8.1),p < 0.001。
- rCBV治疗前94%(IQR 79-103) vs 治疗后89%(IQR 72-103),p = 0.63。
- rCBF治疗前85%(IQR 77-90) vs 治疗后87%(IQR 73-98),p = 0.98。
- 6例未发生迟发性脑缺血所致脑梗死的患者亚组:rCBV治疗前85%(IQR 79-99) vs 治疗后95%(IQR 88-112),p = 0.21;rCBF治疗前81%(IQR 76-87) vs 治疗后89%(IQR 84-99),p = 0.4,约增加10%。
证据类型、等级与局限
- 证据类型:回顾性观察性研究。
- 局限:作者指出研究设计无法量化左西孟旦效应与脑血管痉挛自然演变的区别,需进一步研究。
对床旁实践的改变
- 在难治性脑血管痉挛患者中,左西孟旦使用与少血区Tmax显著降低相关,但Tmax仍处于异常水平,提示持续存在脑血管痉挛。
- 作者认为左西孟旦可能引起脑血管扩张,但因研究设计无法区分左西孟旦效应与血管痉挛自然演变,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Delayed cerebral ischemia associated with cerebral vasospasm (CVS) in aneurysmal subarachnoid hemorrhage significantly affects patient prognosis. Levosimendan has emerged as a potential treatment, but clinical data are lacking. The aim of this study is to decipher levosimendan's effect on cerebral hemodynamics by automated quantitative measurements of brain computed tomography perfusion (CTP).
METHODS: We conducted a retrospective analysis of a database of a neurosurgical intensive care unit. All patients admitted from January 2018 to July 2022 for aneurysmal subarachnoid hemorrhage and treated with levosimendan for CVS who did not respond to other therapies were included. Quantitative measurements of time to maximum (Tmax), relative cerebral blood volume (rCBV), and relative cerebral blood flow (rCBF) were automatically compared with coregistered CTP before and after levosimendan administration in oligemic regions.
RESULTS: Of 21 patients included, CTP analysis could be performed in 16. Levosimendan improved Tmax from 14.4 s (interquartile range [IQR] 9.1-21) before treatment to 7.1 s (IQR 5.5-8.1) after treatment (p < 0.001). rCBV (94% [IQR 79-103] before treatment and 89% [IQR 72-103] after treatment, p = 0.63) and rCBF (85% [IQR 77-90] before treatment and 87% [IQR 73-98] after treatment, p = 0.98) remained stable. The subgroup of six patients who did not develop cerebral infarction attributed to delayed cerebral ischemia showed an approximately 10% increase (rCBV 85% [IQR 79-99] before treatment vs. 95% [IQR 88-112] after treatment, p = 0.21; rCBF 81% [IQR 76-87] before treatment vs. 89% [IQR 84-99] after treatment, p = 0.4).
CONCLUSIONS: In refractory CVS, levosimendan use was associated with a significant reduction in Tmax in oligemic regions. However, this value remained at an abnormal level, indicating the presence of a persistent CVS. Further analysis raised the hypothesis that levosimendan causes cerebral vasodilation, but other studies are needed because our design does not allow us to quantify the effect of levosimendan from that of the natural evolution of CVS.
参考来源
- Cane G, de Courson H, Robert C, et al. Cerebral Hemodynamics and Levosimendan Use in Patients with Cerebral Vasospasm and Subarachnoid Hemorrhage: An Observational Perfusion CT-Based Imaging Study. Neurocrit Care. 2024. PMID: 38326535. doi:10.1007/s12028-023-01928-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。